Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROGLYCERIN vs ISORDIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a vasodilator that is converted to nitric oxide (NO) in vascular smooth muscle cells. NO activates guanylyl cyclase, increasing c GMP levels, leading to dephosphorylation of myosin light chains and vasodilation. Predominantly dilates venous capacitance vessels, reducing preload; also dilates coronary arteries at higher doses.
Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.
Acute angina pectoris,Prophylaxis of angina pectoris,Acute myocardial infarction (IV formulation),Heart failure associated with acute myocardial infarction (IV),Anal fissure (topical, off-label),Esophageal spasm (off-label)
Angina pectoris (prophylaxis and acute treatment),Heart failure (off-label: adjunctive treatment in acute myocardial infarction)
Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses for angina; Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours; Intravenous: 5-200 mcg/min continuous infusion for acute coronary syndromes or heart failure; Topical 2% ointment: 15-30 mg (0.5-1 inch) every 6-8 hours.
Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.
Terminal half-life: 1–4 minutes for the parent compound; clinical effects dissipate within the same time frame, correlating with rapid metabolism.
Terminal half-life: 1–4 hours (isosorbide dinitrate); clinical context: short duration requires frequent dosing or sustained-release formulations.
Metabolized primarily by hepatic glutathione-organic nitrate reductase and cytochrome P450 enzymes (CYP3A4) to inorganic nitrite and denitrated metabolites; also undergoes extrahepatic metabolism in erythrocytes and vascular tissue.
Primarily hepatic via glutathione-organic nitrate reductase; also undergoes denitration to active metabolites (isosorbide-2-mononitrate and isosorbide-5-mononitrate).
Metabolized extensively by hepatic glutathione-organic nitrate reductase and other non-specific esterases; renal excretion of metabolites accounts for approximately 50%, with fecal elimination of about 20-30%. Less than 1% of unchanged drug is excreted renally.
Renal: 80% as inactive metabolites; biliary/fecal: 20% as conjugates.
Approximately 60% bound to albumin.
~28% bound to albumin.
Approximately 3.3 L/kg, indicating extensive distribution into tissues.
2–4 L/kg, indicating extensive tissue distribution.
Sublingual: 40–60% due to first-pass metabolism; buccal: 40–60%; transdermal: 10–20% (limited by skin permeability).
Sublingual: ~40–60% (first-pass bypassed); oral: <30% due to extensive first-pass hepatic metabolism.
No dose adjustment required for any degree of renal impairment, including end-stage renal disease.
No specific GFR-based dose adjustments are recommended; however, caution is advised in severe renal impairment due to potential accumulation of metabolites.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Consider 25% dose reduction; Child-Pugh Class C: Avoid use or use with extreme caution, consider 50% dose reduction.
In Child-Pugh class A: no adjustment. Child-Pugh class B and C: reduce dose by 50% and monitor for hypotension.
Safety and efficacy not established; limited data: IV infusion 0.25-1 mcg/kg/min titrated to effect; sublingual 5-10 mcg/kg per dose (max 0.6 mg) every 5-10 minutes as needed for angina.
Isosorbide dinitrate: not recommended for use in children due to lack of safety and efficacy data; no established pediatric dosing guidelines.
Start at lowest dose; sublingual 0.3 mg, transdermal 0.2 mg/hour; increased sensitivity to hypotension and syncope; monitor for orthostatic hypotension; may require reduced dosing frequency.
Elderly patients may have increased sensitivity to hypotension. Initiate with lowest doses (e.g., 5 mg orally twice daily) and titrate slowly. Monitor blood pressure and orthostatic changes.
Do not use nitroglycerin with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) as this can cause severe hypotension. Concomitant use with soluble guanylyl cyclase stimulators (e.g., riociguat) is contraindicated.
Do not use in patients with erectile dysfunction medications (PDE-5 inhibitors) due to risk of severe hypotension.
Hypotension,Tachycardia,Paradoxical bradycardia,Increased intracranial pressure (use with caution in cerebral hemorrhage or head trauma),Hypertrophic cardiomyopathy (may exacerbate outflow obstruction),Tolerance with prolonged use (intermittent dosing with nitrate-free interval recommended),Abrupt withdrawal may precipitate angina
Hypotension (especially with volume depletion or alcohol),Tolerance with prolonged use (intermittent dosing recommended),Exacerbation of angina upon abrupt withdrawal,Use cautiously in hypertrophic cardiomyopathy
Hypersensitivity to nitroglycerin or any component,Concomitant use with phosphodiesterase-5 inhibitors (within 24 hours for sildenafil, vardenafil; 48 hours for tadalafil),Concomitant use with soluble guanylyl cyclase stimulators (riociguat),Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Constrictive pericarditis,Pericardial tamponade,Restrictive cardiomyopathy,Acute myocardial infarction with low left ventricular filling pressure,Circulatory failure (shock)
Hypersensitivity to nitrates,Concurrent use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil),Severe anemia,Increased intracranial pressure (head trauma, cerebral hemorrhage),Acute circulatory failure (shock, vascular collapse)
Avoid alcohol consumption while taking nitroglycerin due to risk of severe hypotension and syncope. No other significant food interactions.
Avoid excessive alcohol consumption. No specific food interactions; however, high-fat meals may delay absorption of oral formulations. Maintain consistent dietary habits to minimize variations in drug effects.
Insufficient human data; animal studies do not indicate teratogenicity. Avoid in first trimester unless clearly needed. No known increased risk of major malformations. Use caution in third trimester due to potential maternal hypotension reducing uteroplacental perfusion.
Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. It should be used during pregnancy only if clearly needed. Potential fetal risks include hypotension and reduced uteroplacental perfusion, particularly in the first trimester. Second and third trimester risks are theoretical due to maternal hemodynamic changes. Avoid use near term due to risk of neonatal methemoglobinemia. FDA pregnancy category C.
Excreted into breast milk in very low amounts; M/P ratio not established. Considered compatible with breastfeeding; monitor infant for hypotension.
Excretion in human milk is unknown. Due to potential for serious adverse reactions in nursing infants (e.g., methemoglobinemia), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio not reported.
No routine dose adjustment required; however, increased plasma volume may necessitate higher doses for therapeutic effect. Monitor clinical response.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance; however, no specific dose adjustments are established. Use lowest effective dose with careful titration to avoid hypotension. Initiate with 5-10 mg sublingual for acute episodes; for prophylaxis, 10-40 mg orally every 6 hours. Monitor for excessive hypotension.
Use with caution in patients with hypertrophic obstructive cardiomyopathy due to risk of syncope. Nitroglycerin is contraindicated with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to severe hypotension. Sublingual tablets should be taken at first sign of angina; if pain persists after 5 minutes, call 911. Tolerance develops with continuous exposure, so use nitrate-free intervals (10-12 hours daily) for transdermal patches. Administer intravenous nitroglycerin with non-PVC tubing to avoid drug absorption. Monitor for hypotension, reflex tachycardia, and headache. Do not use in patients with severe anemia, increased intracranial pressure, or right ventricular infarction.
Isordil (isosorbide dinitrate) is a nitrate vasodilator used for angina prophylaxis. Sublingual formulation provides rapid onset for acute attacks; oral sustained-release is for chronic prophylaxis. Tolerance develops with continuous exposure; use a daily nitrate-free interval of 10-12 hours. Avoid use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) due to severe hypotension. Monitor for headache, hypotension, and reflex tachycardia.
Take sublingual nitroglycerin at the first sign of chest pain; sit down before taking to prevent dizziness.,Place the tablet under the tongue or in the buccal pouch and allow it to dissolve completely; do not swallow.,If pain is not relieved within 5 minutes, call 911 immediately; you may take a second tablet while waiting.,Do not take this medication if you have taken erectile dysfunction drugs (e.g., sildenafil, tadalafil) within the last 24-48 hours.,Store sublingual tablets in the original glass bottle with the cap tightly closed to protect from light and moisture; do not transfer to another container.,Expect a headache or flushing after taking; these usually diminish with continued use.,If using a transdermal patch, apply to a hairless area of skin and rotate sites daily; remove at bedtime to prevent tolerance.,Avoid alcohol while taking this medication as it can increase the risk of hypotension.,Seek emergency help if you experience severe dizziness, fainting, or difficulty breathing.
Take sublingual isordil at the first sign of an angina attack; sit down before using to avoid dizziness.,For chronic prophylaxis, take as prescribed; do not skip doses to maintain the nitrate-free interval.,Avoid alcohol as it can increase the risk of hypotension and dizziness.,Report any severe headaches, worsening chest pain, or fainting to your healthcare provider immediately.,Never take erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on isordil.
"Concomitant use of nitroglycerin, a vasodilator that increases cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, and acebutolol, a cardioselective beta-1 adrenergic blocker, can lead to excessive hypotension and reflex tachycardia. Acebutolol may blunt the compensatory sympathetic response to nitroglycerin-induced vasodilation, while nitroglycerin can counteract the negative chronotropic effects of acebutolol, resulting in unopposed vagal tone and potential bradycardia. This interaction increases the risk of syncope, dizziness, and cardiovascular collapse, particularly in patients with volume depletion or pre-existing heart failure."
"Amobarbital, a barbiturate with hepatic enzyme-inducing properties, may enhance the metabolism of nitroglycerin, potentially reducing its efficacy. However, the primary concern is that amobarbital can cause significant hypotension via central nervous system depression and vasodilation, which, when combined with the vasodilatory effects of nitroglycerin, may lead to additive hypotensive effects, increasing the risk of severe hypotension, syncope, and cardiovascular collapse. This interaction is particularly relevant in patients with coronary artery disease or heart failure, where maintaining adequate blood pressure is critical."
"Concurrent administration of clofarabine, a purine nucleoside antimetabolite, and nitroglycerin, a vasodilator for angina, may lead to additive hypotension. Clofarabine itself can induce hypotension as an adverse effect, and nitroglycerin directly relaxes vascular smooth muscle, resulting in decreased blood pressure. This combination increases the risk of severe hypotension, potentially leading to dizziness, syncope, or falls, especially in patients with pre-existing hypotension or volume depletion."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROGLYCERIN vs ISORDIL, answered by our medical review team.
NITROGLYCERIN is a Nitrate Vasodilator that works by Nitroglycerin is a vasodilator that is converted to nitric oxide (NO) in vascular smooth muscle cells. NO activates guanylyl cyclase, increasing c GMP levels, leading to dephosphorylation of myosin light chains and vasodilation. Predominantly dilates venous capacitance vessels, reducing preload; also dilates coronary arteries at higher doses.. ISORDIL is a Nitrate Vasodilator that works by Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROGLYCERIN and ISORDIL depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROGLYCERIN is: Sublingual: 0.3-0.6 mg every 5 minutes up to 3 doses for angina; Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours; Intravenous: 5-200 mcg/min continuous infusion for acute coronary syndromes or heart failure; Topical 2% ointment: 15-30 mg (0.5-1 inch) every 6-8 hours.. The standard adult dose of ISORDIL is: Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROGLYCERIN and ISORDIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROGLYCERIN is classified as Category C. Insufficient human data; animal studies do not indicate teratogenicity. Avoid in first trimester unless clearly needed. No known increased risk of major malformations. Use caution . ISORDIL is classified as Category C. Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.